newsfilter
← Latest News
Business Wire·

Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

- Initial data from ongoing Phase 2a study in geographic atrophy demonstrated ability of GEM103 to durably regulate complement and showed a differentiated safety profile with no increased risk of CNV - Completed enrollment in Phase 2a study of GEM10